Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Research & Development (2023 - 2025)

Historic Research & Development for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $31.4 million.

  • Day One Biopharmaceuticals' Research & Development fell 638.8% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.0 million, marking a year-over-year decrease of 1683.68%. This contributed to the annual value of $227.7 million for FY2024, which is 7445.62% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Research & Development stood at $31.4 million, which was down 638.8% from $36.1 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Research & Development peaked at $92.1 million during Q2 2024, and registered a low of $31.4 million during Q3 2025.
  • For the 3-year period, Day One Biopharmaceuticals' Research & Development averaged around $43.8 million, with its median value being $36.7 million (2023).
  • Its Research & Development has fluctuated over the past 5 years, first surged by 18620.35% in 2024, then crashed by 6075.28% in 2025.
  • Over the past 3 years, Day One Biopharmaceuticals' Research & Development (Quarter) stood at $37.3 million in 2023, then skyrocketed by 65.53% to $61.8 million in 2024, then crashed by 49.18% to $31.4 million in 2025.
  • Its Research & Development was $31.4 million in Q3 2025, compared to $36.1 million in Q2 2025 and $39.6 million in Q1 2025.